Market Place
Sourcing Support
Ionis` Method To The Madness For Drug Name Tournament Win
15 Apr 2026 //
FIERCE PHARMA
Ionis Announces Changes To Board Of Directors
09 Mar 2026 //
BUSSINESSWIRE
Ionis Reveals 2025 Financial Results And Program Advancements
25 Feb 2026 //
PHARMIWEB
Ionis To Present At Upcoming Investor Conferences
19 Feb 2026 //
BUSINESSWIRE
Ionis Reschedules Q4 & Full Year 2025 Financial Results Webcast
17 Feb 2026 //
BUSINESSWIRE
Ionis To Host Q4 & Full Year 2025 Financial Results Webcast
11 Feb 2026 //
BUSINESSWIRE
Ionis To Present At 44th Annual J.P. Morgan Healthcare Conference
06 Jan 2026 //
BUSINESSWIRE
Ionis Prices Offering To Refinance 2026 Convertible Notes
13 Nov 2025 //
BUSINESSWIRE
Ionis To Present At Upcoming Investor Conferences
12 Nov 2025 //
BUSINESSWIRE
Ionis Plans Convertible Offering To Refinance 2026 Notes
11 Nov 2025 //
BUSINESSWIRE
Ionis Highlights Progress On Key Programs In Q3 Financial Result
29 Oct 2025 //
BUSINESSWIRE
Ionis Ranks 2nd In Science Magazine`s Top Employer List
23 Oct 2025 //
BUSINESSWIRE
Ionis To Hold Third Quarter 2025 Financial Results Webcast
16 Oct 2025 //
BUSINESS WIRE
Ionis Highlights Innovative Pipeline at Innovation Day
07 Oct 2025 //
BUSINESSWIRE
Ionis Marks Decade of Adaptive Experience for Neuro Patients
12 Sep 2025 //
BUSINESSWIRE
Ionis` Tryngolza Win in sHTG Sends Shares Soaring by 27%
03 Sep 2025 //
BUSINESSWIRE
Ionis Q2 2025 Financial Results and Key Program Progress
30 Jul 2025 //
BUSINESSWIRE
Phase 3 OASISplus Donidalorsen Data Published in JACI In Practice
21 Jul 2025 //
BUSINESSWIRE
Ionis` Q2 2025 Financial Results Webcast Scheduled
16 Jul 2025 //
BUSINESSWIRE
Ionis reports Positive Results from Essence study of olezarsen
19 May 2025 //
BUSINESSWIRE
Ionis to host 2025 virtual Annual Meeting of Stockholders
06 May 2025 //
BUSINESSWIRE
Ionis reports first quarter 2025 financial results
30 Apr 2025 //
BUSINESSWIRE
HAE Patients Want New Therapies, Poll Finds 90% Dissatisfied
29 Apr 2025 //
BUSINESSWIRE
Ionis to hold first quarter 2025 financial results webcast
16 Apr 2025 //
BUSINESSWIRE
Ionis to host expert panel discussion on sHTG
03 Apr 2025 //
BUSINESSWIRE
Ionis to present at upcoming investor conferences
25 Feb 2025 //
BUSINESSWIRE
New Donidalorsen Data Shows Sustained HAE Attack Rate Reduction
20 Feb 2025 //
BUSINESSWIRE
Ionis reports fourth quarter and full year 2024 financial results
19 Feb 2025 //
BUSINESSWIRE
Ionis to hold Q4 and full year 2024 financial results webcast
05 Feb 2025 //
BUSINESSWIRE
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
08 Jan 2025 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
07 Nov 2024 //
PR NEWSWIRE
Ionis reports Q3 2024 financial results
06 Nov 2024 //
PR NEWSWIRE
Ionis to hold third quarter 2024 financial results webcast
23 Oct 2024 //
PR NEWSWIRE
Ionis announces proposed public offering of common stock
09 Sep 2024 //
PR NEWSWIRE
Ionis announces pricing of $500.3 million public offering
09 Sep 2024 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
28 Aug 2024 //
PR NEWSWIRE
Ionis Drops Eye Disease Target For Roche-Partnered Drug
01 Aug 2024 //
FIERCE BIOTECH
Ionis reports second quarter 2024 financial results
01 Aug 2024 //
PR NEWSWIRE
Ionis to hold second quarter 2024 financial results webcast
19 Jul 2024 //
PR NEWSWIRE
Ionis Announces olezarsen FCS NDA Accepted for Priority Review
25 Jun 2024 //
PR NEWSWIRE
Ionis Expands Licensing Agreement With Otsuka For Donidalorsen In Angioedema
18 Jun 2024 //
PR NEWSWIRE
Ionis To Present At TD Cowen Genetic Medicines & RNA Summit
17 Jun 2024 //
PR NEWSWIRE
Ionis Positive Donidalorsen Data In Hereditary Angioedema
31 May 2024 //
PR NEWSWIRE
Ionis to hold donidalorsen Phase 3 data webcast
28 May 2024 //
PR NEWSWIRE
Wainua™ Neuro-Ttransform Isa Data: To Be Presented At 2024 Symposium
23 May 2024 //
PR NEWSWIRE
Biogen, Ionis to discontinue development of experimental ALS drug
17 May 2024 //
REUTERS
Ionis to host 2024 virtual Annual Meeting of Stockholders
15 May 2024 //
PR NEWSWIRE
Ionis reports first quarter 2024 financial results
07 May 2024 //
PR NEWSWIRE
Ionis Publishes 2023 Corporate Responsibility Report
25 Apr 2024 //
PR NEWSWIRE
AstraZeneca drops GOLDILOX and the porcupine in R&D update
24 Apr 2024 //
FIERCE BIOTECH
Ionis to hold first quarter 2024 financial results webcast
23 Apr 2024 //
PR NEWSWIRE
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
13 Mar 2024 //
FIERCE BIOTECH
Ionis announces new chief global product strategy officer
29 Feb 2024 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
28 Feb 2024 //
PR NEWSWIRE
Ionis reports fourth quarter and full year 2023 financial results
21 Feb 2024 //
PR NEWSWIRE
Ionis to hold fourth quarter and full year 2023 financial results webcast
07 Feb 2024 //
PR NEWSWIRE
Ionis’ HAE drug wins in phase 3 setting up approval run to FDA
22 Jan 2024 //
FIERCE BIOTECH
Ionis poised for continued momentum in 2024 with product launches
08 Jan 2024 //
PR NEWSWIRE
Ionis announces European licensing agreement with Otsuka for donidalorsen
18 Dec 2023 //
PR NEWSWIRE
Ionis announces the appointment of Michael Yang to Board of Directors
14 Dec 2023 //
PR NEWSWIRE
